Exscientia  a world-leading Artificial Intelligence (AI)-driven drug discovery company  announced today that it has entered a three-year AI drug discovery partnership with leading biopharma company Celgene  including an initial $25 million upfront payment and eligibility to receive substantial milestones based on the clinical  regulatory and commercial success of the program